Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Xenon Pharmaceuticals Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 5 examiners and 4 art units, indicating both examiner overlap and technical-unit breadth.
SOROUSH, LAYLA is the busiest examiner, with 2 pending matters. Counsel can coordinate the matters assigned to that examiner while maintaining separate strategies for the remaining examination relationships.
The distribution supports portfolio-level tracking of recurring pharmaceutical issues, alongside matter-specific review of examiner positions and claim scope.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §102 only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SOROUSH, LAYLA | 2 | 40.5% | +43.4% |
| CARCANAGUE, DANIEL R | 1 | 80.8% | +24.5% |
| HUTTER, GILLIAN A | 1 | 54.5% | +46.0% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746981 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | CARCANAGUE, DANIEL R | 196d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18330100 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18746981 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | CARCANAGUE, DANIEL R | 196d overdue |
| 18415139 | METHODS FOR TREATING PAIN | SZNAIDMAN, MARCOS L | 19d overdue |
| 18330100 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | 13d |
| 19094303 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | SOROUSH, LAYLA | 14d |
| 18603554 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | HUTTER, GILLIAN A | 46d |
| 19008882 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1628 | 2 |
| 1621 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19094303 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | SOROUSH, LAYLA | 1622 | §103DP | Final Rejection | 14d | Pending | Mar 28, 2025 |
| 19008882 | METHODS FOR ENHANCING THE BIOAVAILABILITY AND EXPOSURE OF A VOLTAGE-GATED POTASSIUM CHANNEL OPENER | SOROUSH, LAYLA | 1622 | §103DP | Non-Final OA | — | Pending | Jan 03, 2025 |
| 18746981 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | CARCANAGUE, DANIEL R | 1621 | §102Other | Non-Final OA | 196d overdue | Pending | Jun 18, 2024 |
| 18603554 | CONJOINT THERAPY FOR TREATING SEIZURE DISORDERS | HUTTER, GILLIAN A | 1625 | §103 | Final Rejection | 46d | Pending | Mar 13, 2024 |
| 18415139 | METHODS FOR TREATING PAIN | SZNAIDMAN, MARCOS L | 1628 | §103 | Final Rejection | 19d overdue | Pending | Jan 17, 2024 |
| 18330100 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | LEE, CHIHYI NMN | 1628 | §102§103§112 | Final Rejection | 13d | Pending | Jun 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXenon Pharmaceuticals Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Layla Soroush has the most, with 2 of Xenon Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
